Powerwalker wrote first @ #86824 expressing the idea more succinctly. I did not see that when I wrote mine, but thank you. That is what I love about I-Hub is there are a good many clear thinkers and good honest writers and contributors and very few "polluters" who come and go but are fairly dealt with by the moderators. (My personal opinion is they as maladjusted children just trying to get attention by way of a negative response)
But back to your Bioverariv thread, I think it is a spin off onto an IPO and they will float shares on the market with BIIB shareholders being granted a dividend of shares> Biogen will get its cash from the IPO and the existing Shareholders, if history of this types of transactions holds true, will be very happy. Maybe I am misunderstanding but from the looks of it Biogen will divest to the BIIB shareholders and to the general market as an IPO shares of a new company. If I am not mistaken net cash to Biogen (or value of all IPO shares)was slated at $5.6 Bil. Theoretically, one would expect a commensurate drop in BIIB share price for not having those assets. But what happens in the case of well regarded companies it that it has a paradoxical effect of lowering the "book value" but raising the "enterprise value," the stock price. The theory is that this well managed growth company can make better use of the $5.6 Bil as cash than the $5.6 Bil as the slow growth but steady income value asset of the hemophilia division.
But what do I know I am I unabashedly LONG AVXL Stockholder and must be stupid because Anavex Shareholders have been Decreed as such by Lord Adam Fueurenstien, Duke of Prognostia and Barron of Fallacy.
Go Anavex/Biogen- Crush MS with the historic partnership!
Market Data 
Markets 
AI
